Expression level and clinical significance of serum exosomal miR-744-5p in non-small cell lung cancer
10.3760/cma.j.issn.1009-9158.2020.02.008
- VernacularTitle: 血清外泌体miR-744-5p在非小细胞肺癌中的表达水平及其临床意义
- Author:
Shaopeng LI
1
;
Xin ZHANG
;
Han ZHANG
;
Lei ZHENG
Author Information
1. Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Exosomes;
microRNAs;
Biomarkers, tumor
- From:
Chinese Journal of Laboratory Medicine
2020;43(2):142-146
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analysis the expression level and clinical value of serum exosomal miR-744-5p in non-small cell lung cancer (NSCLC).
Methods:Retrospective study. A total of 183 subjects, including 92 NSCLC patients and 91 healthy controls, were recruited from Nanfang Hospital Affiliated to Southern Medical University from November 2016 to February 2018. Exosomes were extracted using ExoQuick and the total RNA was extracted from the exosomes.The expression level of serum exosomal miR-744-5p was assessed by real-time fluorescent quantitative polymerase chain reaction (qRT-PCR). The diagnostic efficiency of exosomal miR-744-5p was evaluated by receiver operating characteristic (ROC) curve.
Results:The qRT-PCR results revealed that the expression level of serum exosomal miR-744-5p in patients with NSCLC (0.012 2±0.019 7) was significantly lower than that in the healthy control (0.093 6±0.081 9), and the difference was statistically significant (U=553.5, P<0.001). Furthermore, the level of miR-744-5p in patients with early stage (stage Ⅰ and Ⅱ) lung cancer(0.011 7±0.013 9) was significantly different, when compared to healthy controls (U=72.5, P<0.001). The exosomal level of miR-744-5p in samples (0.010 6±0.020 3) was lower than that in squamous cell carcinoma serum (0.017 3±0.017 8) , and the difference was statistically significant (U=394.5, P<0.001). The ROC curve revealed that miR-744-5p expression can be a significant biomarker to discriminate between normal and NSCLC cases, with an area under the ROC curve of 0.933 9 (95%CI=0.899 6-0.968 1, P<0.000 1). MiR-744-5p can effectively diagnose early stage NSCLC, with an area under the ROC curve of 0.943 1 (95%CI=0.883 7-1.000 0, P<0.000 1).
Conclusion:The serum exosomal miR-744-5p could serve as a non-invasive biomarker for the diagnosis of NSCLC, but further comparative research and expanded verification are needed.
